Glucose-6-phosphate dehydrogenase: a therapeutic target for ovarian cancer

IntroductionOvarian cancer (OC) is a gynecological tumor disease, which is usually diagnosed at an advanced stage and has a poor prognosis. It has been established that the glucose metabolism rate of cancer cells is significantly higher than that of normal cells, and the pentose phosphate pathway (PPP) is an important branch pathway for glucose metabolism. Glucose-6-phosphate dehydrogenase (G6PD) is the key rate-limiting enzyme in the PPP, which plays an important role in the initiation and development of cancer (such as OC), and has been considered as a promisinganti-cancer target.Areas coveredIn this review, based on the structure and biological function of G6PD, recent research on the roles of G6PD in the progression, metastasis, and chemoresistance of OC are summarized and accompanied by proposed molecular mechanisms, which may provide a systematic understanding of targeting G6PD for the treatment of patients with OC.Expert opinionAccumulating evidence demonstrates that G6PD is a promising target of cancer. The development of G6PD inhibitors for cancer treatment merits broad application prospects.

Automated summary

This review summarizes the role of glucose-6-phosphate dehydrogenase (G6PD) in the progression, metastasis, and chemoresistance of ovarian cancer (OC), and proposes potential molecular mechanisms, providing a systematic understanding of targeting G6PD for the treatment of OC patients.